GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (NAS:CRDF) » Definitions » Cyclically Adjusted Price-to-FCF

CRDF (Cardiff Oncology) Cyclically Adjusted Price-to-FCF : (As of Jul. 08, 2025)


View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cardiff Oncology Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Cardiff Oncology's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Cyclically Adjusted Price-to-FCF Chart

Cardiff Oncology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cardiff Oncology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cardiff Oncology's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Cardiff Oncology's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiff Oncology's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Cyclically Adjusted Price-to-FCF falls into.


;
;

Cardiff Oncology Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Cardiff Oncology's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Cardiff Oncology's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.192/134.9266*134.9266
=-0.192

Current CPI (Mar. 2025) = 134.9266.

Cardiff Oncology Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -17.211 100.684 -23.064
201509 -14.079 100.392 -18.922
201512 -18.599 99.792 -25.147
201603 -17.388 100.470 -23.351
201606 -20.185 101.688 -26.783
201609 -17.029 101.861 -22.557
201612 -21.150 101.863 -28.015
201703 -20.393 102.862 -26.750
201706 -10.712 103.349 -13.985
201709 -13.261 104.136 -17.182
201712 -5.896 104.011 -7.648
201803 -3.720 105.290 -4.767
201806 -2.628 106.317 -3.335
201809 -1.012 106.507 -1.282
201812 -0.943 105.998 -1.200
201903 -0.823 107.251 -1.035
201906 -0.637 108.070 -0.795
201909 -0.539 108.329 -0.671
201912 -0.392 108.420 -0.488
202003 -0.340 108.902 -0.421
202006 -0.296 108.767 -0.367
202009 -0.151 109.815 -0.186
202012 -0.139 109.897 -0.171
202103 -0.158 111.754 -0.191
202106 -0.111 114.631 -0.131
202109 -0.138 115.734 -0.161
202112 -0.182 117.630 -0.209
202203 -0.241 121.301 -0.268
202206 -0.162 125.017 -0.175
202209 -0.183 125.227 -0.197
202212 -0.213 125.222 -0.230
202303 -0.194 127.348 -0.206
202306 -0.165 128.729 -0.173
202309 -0.185 129.860 -0.192
202312 -0.160 129.419 -0.167
202403 -0.175 131.776 -0.179
202406 -0.206 132.554 -0.210
202409 -0.223 133.029 -0.226
202412 -0.189 133.157 -0.192
202503 -0.192 134.927 -0.192

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cardiff Oncology  (NAS:CRDF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Cardiff Oncology Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiff Oncology Business Description

Industry
Traded in Other Exchanges
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
Executives
James E. Levine officer: Chief Financial Officer 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Gary W Pace director C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Fairooz Kabbinavar officer: Chief Medical Officer C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark Erlander officer: Chief Scientific Officer C/O TROVAGENE, INC., 11055 FLINTKOTE AVENUE, SUITE A, SAN DIEGO CA 92121
Lale White director 310 GODDARD, SUITE 150, IRVINE CA 92618
James O Armitage director C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
Tod Smeal officer: Chief Scientific Officer 11055 FLINTKOTE AVENUE, SA DIEGO CA 92121
Katherine L Ruffner officer: Chief Medical Officer 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
Mani Mohindru director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Rodney S Markin director C/O UNIVERSITY OF NEBR MEDICAL CENTER, 983135 NEBRASKA MEDICAL CENTER, OMAHA NE 68198-3135
Gary S Jacob director
Vicki Kelemen officer: Exec. VP and COO 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116